Madrigal Pharmaceuticals (MDGL) Capital Expenditures Growth (5y) (2015 - 2026)
Powered by 
Analysis
Madrigal Pharmaceuticals (MDGL) Capital Expenditures Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Madrigal Pharmaceuticals | 15.77 Bn | 14.93 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 362.95% |
| Mar 31, 2026 | 144.56% |
| Dec 31, 2025 | -110.16% |
| Sep 30, 2025 | 209.86% |
| Dec 31, 2024 | -25.66% |
| Sep 30, 2024 | 230.02% |
| Jun 30, 2024 | 165.93% |
| Mar 31, 2024 | 54.16% |
| Dec 31, 2023 | 164.52% |
| Sep 30, 2023 | 91.98% |
| Mar 31, 2023 | 103.62% |
| Dec 31, 2022 | -25.34% |
| Jun 30, 2022 | -3.49% |
| Mar 31, 2022 | 91.86% |
| Dec 31, 2021 | 124.08% |
| Dec 31, 2020 | 15.37% |
| Sep 30, 2020 | 15.53% |
| Jun 30, 2020 | 15.15% |
| Mar 31, 2020 | 3.93% |
| Dec 31, 2019 | 70.86% |